Home›Stocks›BBNX

BBNX — structural market context

Beta Bionics, Inc.

Structural market context from public regulatory and market data, shown with its as-of dates. Descriptive only: nothing on this page is a recommendation, a prediction, or advice to buy or sell any security.

What changed

As of the close on Oct 16. Each line shows the earlier value, the later value and their dates.

Price

Close $16.35 (Oct 16) vs $17.31 (Oct 15): −5.55%.

Volume

0.63× its 20-session average (1.1M) on Oct 16.

Includes pre- and post-market trading.

Short interest

Short interest 6.0M shares (settlement Sep 30) vs 10.6M (Sep 15).

No new publication in this window. Latest: settlement Sep 30, published Oct 10.

Fails-to-deliver

Latest file (settlements Sep 15–Sep 30, published Oct 16): 2 days with fails, largest 8K shares on Sep 18.

Previous file (settlements Sep 1–Sep 14, published Sep 30): 1 day with fails, largest 2K shares on Sep 3.

Analyst rating actions

None recorded in this window.

Insider filings (Form 4)

1 Form 4 filing recorded, with 1 transaction: 0 purchase transactions (code P, $0), 1 sale transaction (code S, $13K).

Filed Oct 16. Form 4 data arrives about a day after filing.

BBNX short interest & days to cover

SHARES SHORT
6.0M
% OF FLOAT
—
DAYS TO COVER
3.3
CHANGE VS PRIOR
-43.0%

FINRA consolidated short interest, reported twice a month and published ~2 weeks after each settlement date. % of float uses reported free float. · as of 2026-09-30 (17d ago)

BBNX fails-to-deliver (FTD)

Settlement dateFailed sharesPrice
2026-09-18 · 29d8K$21.43
2026-09-17 · 30d6K$22.18
2026-09-03 · 44d2K$19.42

SEC fails-to-deliver files, published twice a month with ~6 weeks of delay.

BBNX insider buying and selling (Form 4)

Last 12 months, Form 4 codes P and S: 0 purchases · 13 sales · 1 filing not counted

InsiderTypeSharesValueFiled
Hopman Mark · officer: Chief Commercial OfficerSell (S)775$13K2026-10-16
Hopman Mark · officer: Chief Commercial OfficerSell (S)370$7K2026-10-05
Jones Christy · directorSell (S)6K$148K2026-09-23
Hopman Mark · officer: Chief Commercial OfficerSell (S)36K$665K2026-09-18
Mensinger Mike · officer: Chief Product OfficerSell (S)3K$58K2026-09-17

SEC Form 4 filings: purchases and sales reported on Form 4 (transaction codes P and S) only; grants and option exercises excluded. Attributed public records.

BBNX analyst ratings

FirmActionRatingPublished
JefferiesinitialiseBuy2026-10-12
Jefferiesprice_target—2026-10-12
BarclaysinitialiseOverweight2026-10-06
Barclaysprice_target—2026-10-06
Wells Fargoprice_target—2026-09-23

Rating actions as published by the firms, from public feeds. They are not graded here.

Frequently asked questions

Are insiders buying BBNX?
In the last 12 months of SEC Form 4 filings, BBNX recorded 0 insider purchases and 13 sales reported on Form 4 (transaction codes P and S; grants and option exercises excluded). 1 filing not counted: the filed price could not be checked against the U.S. listing. These are attributed public records — information, not instruction.
What do analysts say about BBNX?
The most recent action: Jefferies initialise to Buy on 2026-10-12. Rating actions are shown as published by the firms; they are not graded here.
Is this page telling me to buy or sell BBNX?
No. Everything on this page is descriptive, structural market context from public data, shown with its as-of dates. TradeAI News does not issue directional recommendations, price predictions, or buy/sell advice — for any ticker.
All covered stocksShort Interest & FTD trackerInsider Buying trackerThe platform

More tickers starting with B

BABA · Alibaba Group Holding LimitedBE · Bloom Energy CorporationBTI · British American Tobacco p.l.cBCDA · BioCardia, Inc.BELFB · Bel Fuse Inc.BFLY · Butterfly Network, Inc.All B →

This is the teaser.

Latest rows shown. Full history, market-wide screens, cluster detection and the context journal live in the dashboard.

Start free →View plans →

Not financial advice. Trading involves risk. Descriptive structural context, never a recommendation.